Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
SOMATIC DNA MUTATIONS, MSI STATUS, MUTATIONAL LOAD (ML): ASSOCIATION WITH OVERALL SURVIVAL (OS) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) OF CALGB/SWOG 80405 (ALLIANCE)
29 března, 2021 9:33 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3504 Citation: J Clin Oncol 35,...
Post-Surgery Capecitabine ‘Should Become Standard of Care’ in Biliary Tract Cancers
29 března, 2021 9:26 pmJune 4, 2017 In a study of 447 patients with biliary tract cancers, capecitabine improved overall survival (OS) when...
VYBRANÉ NOVINKY ZAMĚŘENÉ NA ZHOUBNÉ NÁDORY ZAŽÍVACÍHO TRAKTU
29 března, 2021 9:23 pmAdjuvantní chemoterapie karcinomu tlustého střeva (CC) – čas ke změně Prospektivní analýza šesti adjuvantních klinických studií je odrazovým můstkem ke změně...
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
12 března, 2021 7:36 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9504 Authors: Reinhard Dummer, Paolo Antonio Ascierto,...
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study
12 března, 2021 7:33 pmMeeting: 2018 ASCO Annual Meeting Track: Patient and Survivor Care Abstract number: 10 038 Authors: Francesco De...
Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma
12 března, 2021 7:32 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9552 Authors: Allison Betof Warner, Alexander Noor...
4-YEAR SURVIVAL AND OUTCOMES AFTER CESSATION OF PEMBROLIZUMAB (PEMBRO) AFTER 2-YEARS IN PATIENTS (PTS) WITH IPILIMUMAB (IPI)-NAIVE ADVANCED MELANOMA IN KEYNOTE-006
12 března, 2021 7:30 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin cancers Abstract number: 9503 Authors: Georgina V. Long, Jacob Schachter,...
Four-Year Data Show Durable Effect of Pembrolizumab in Advanced Melanoma
12 března, 2021 7:28 pmJune 4, 2018 The anti–PD-1 antibody pembrolizumab previously demonstrated superior overall survival (OS) in patients with advanced melanoma compared...
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358
12 března, 2021 7:25 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9505 Authors: Suzanne Louise Topalian, Shailender Bhatia,...
Neoadjuvant Nivolumab Leads to Tumor Regression in Resectable Merkel Cell Carcinoma
12 března, 2021 7:20 pmJune 4, 2018 The PD-1/PD-L1 pathway is commonly upregulated in Merkel cell carcinoma (MCC), a rare aggressive form of...